2014 Press Releases

Keyword Search
 
2014 | 2013 | 2012 | 2011
DateTitle 
12/15/14Data Presented by Independent Academic Collaborators Demonstrate Ability of Novel Manocept™ Immunotherapy to Kill Activated Macrophages from KS PatientsDownload PDF
12/12/14Macrophage Therapeutics to Present Data Supporting Potential for Breakthrough with Manocept™ in ImmunotherapyDownload PDF
12/10/14Navidea Forms Macrophage Therapeutics Business Unit to Explore Therapeutic Applications of Manocept™Download PDF
11/25/14Navidea Biopharmaceuticals to Present at the 2014 LD Micro ConferenceDownload PDF
11/20/14European Commission Approves Navidea’s Sentinel Lymph Node Detection Agent Lymphoseek®Download PDF
11/11/14Navidea Receives $1.1Million PDUFA Filing Fee Refund for Award of Orphan Drug Status; Platinum Partners Reaffirms Commitment to Line of CreditDownload PDF
11/06/14Navidea Announces Third Quarter 2014 Financial ResultsDownload PDF
10/30/14Navidea Announces Scientific Presentations of Results from Lymphoseek® Studies at the European Association of Nuclear Medicine and European Society of Surgical Oncology MeetingsDownload PDF
10/29/14Navidea Biopharmaceuticals to Announce Third Quarter 2014 Financial Results on November 6, 2014Download PDF
10/15/14Navidea Announces Rick Gonzalez as New Chief Executive OfficerDownload PDF
10/15/14FDA Approves Expanded Use of Navidea’s Lymphoseek® for Lymphatic Mapping in Solid TumorsDownload PDF
09/29/14Navidea to Participate in the BTIG Emerging Technologies in Healthcare Diagnostics Investor Conference September 30thDownload PDF
09/26/14Navidea’s Lymphoseek® Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck CancersDownload PDF
09/23/14Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical CancerDownload PDF
09/18/14Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck CancersDownload PDF
09/04/14Navidea Enters Lymphoseek® Development and Commercialization Agreement for ChinaDownload PDF
08/06/14Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 MillionDownload PDF
07/29/14Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014Download PDF
07/17/14Navidea Biopharmaceuticals Announces 2014 Annual Meeting ResultsDownload PDF
07/16/14Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic DiseasesDownload PDF
07/02/14Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014Download PDF
06/17/14Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare ConferenceDownload PDF
06/13/14U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node BiopsyDownload PDF
06/11/14Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc AnalysisDownload PDF
06/10/14Navidea Announces Data Demonstrating Potential of Manocept™ Platform to Diagnose Rheumatoid Arthritis and Kaposi’s SarcomaDownload PDF
06/10/14Navidea Biopharmaceuticals Announces Positive Lymphoseek® (technetium Tc 99m tilmanocept) Injection Results on Injection Timing and Surgery Across Multiple Solid Tumor TypesDownload PDF
05/29/14Navidea Biopharmaceuticals to Present at the Jefferies 2014 Global Healthcare ConferenceDownload PDF
05/20/14Navidea Announces Eleven Scientific Presentations of Results from Lymphoseek® and Manocept™ Studies at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingDownload PDF
05/15/14Navidea Announces Restructuring of Pipeline DevelopmentDownload PDF
05/07/14Navidea Biopharmaceuticals Announces First Quarter 2014 Financial ResultsDownload PDF
04/29/14Navidea Biopharmaceuticals to Announce First Quarter 2014 Financial Results on May 7, 2014Download PDF
04/17/14Navidea Biopharmaceuticals Provides Progress Updates on Lymphoseek® ProgramsDownload PDF
04/10/14Navidea Announces Presentation of Study Findings of Manocept™ Platform Imaging Agent in Kaposi Sarcoma at AACR Annual MeetingDownload PDF
03/26/14Navidea Announces Presentations Highlighting NAV4694 Beta-Amyloid, PET Imaging Agent at the German Society of Nuclear Medicine CongressDownload PDF
03/19/14Navidea Biopharmaceuticals Provides Update on European Marketing Authorization Application for Lymphoseek®Download PDF
03/14/14Navidea Biopharmaceuticals Announces Presentation of Lymphoseek® Three-Year Recurrence and Survival Outcomes after Sentinel Lymph Node Biopsy in Patients with Breast Cancer and MelanomaDownload PDF
03/06/14Navidea Announces Fourth Quarter and Full Year 2013 ResultsDownload PDF
03/06/14Navidea Biopharmaceuticals Closes $30 Million Loan with Oxford Finance, LLCDownload PDF
03/05/14Navidea Announces Acceptance for Review of an Additional sNDA to Further Expand Lymphoseek® LabelingDownload PDF
03/03/14Navidea Biopharmaceuticals to Announce Fourth Quarter and Full-Year 2013 Financial Results on Thursday, March 6, 2014Download PDF
02/19/14Navidea Biopharmaceuticals Adds New Member to Board of DirectorsDownload PDF
02/18/14Navidea Announces Priority Review for the sNDA to Expand Lymphoseek® Labeling for Sentinel Lymph Node Detection in Patients with Head and Neck CancerDownload PDF
02/13/14Navidea Biopharmaceuticals Announces the Presentation of Manocept™ Data at Keystone Symposia for Molecular Cell Biology of Macrophages in Human DiseaseDownload PDF
02/06/14Navidea Biopharmaceuticals Announces Positive Initial Results in Single-Center Cohort from Phase 2b Trial of NAV4694 in Subjects with Mild Cognitive Impairment (MCI)Download PDF
02/04/14Navidea Biopharmaceuticals to Present at the 16th Annual BIO CEO and Investor ConferenceDownload PDF
01/07/14Navidea Biopharmaceuticals Expands Lymphoseek® Global Commercialization EffortsDownload PDF
01/07/14Navidea Biopharmaceuticals to Present at 2014 Biotech Showcase™ ConferenceDownload PDF